The role of central noradrenergic dysregulation in anxiety disorders: Evidence from clinical studies

Journal of Psychopharmacology

Volumn 25, Issue 1, 2011, Pages 3-16

  Kalk, N J ^a   Nutt, D J ^b   Lingford Hughes, A R ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Anxiety disorders; noradrenaline

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CARBON DIOXIDE; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GROWTH HORMONE; HYDROCORTISONE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; NORADRENALIN; PAROXETINE; PLACEBO; REBOXETINE; SERTRALINE; VENLAFAXINE; YOHIMBINE;

ANXIETY DISORDER; BLOOD INJURY PHOBIA; BLOOD PRESSURE; CLINICAL TRIAL; COMORBIDITY; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; GENERALIZED ANXIETY DISORDER; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; LOW DRUG DOSE; MAJOR DEPRESSION; NORADRENERGIC SYSTEM; OBSESSIVE COMPULSIVE DISORDER; PANIC; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW; SOCIAL PHOBIA; TREATMENT RESPONSE;

ADRENERGIC UPTAKE INHIBITORS; ANXIETY DISORDERS; CLINICAL TRIALS AS TOPIC; HUMANS; NOREPINEPHRINE; PANIC DISORDER; PHOBIC DISORDERS; RECEPTORS, ADRENERGIC, ALPHA-2; SYMPATHETIC NERVOUS SYSTEM;

EID: 78650611352     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110367448     Document Type: Review

References (129)

1. Abelson JL, Glitz D., Cameron OG, Lee MA, Bronzo M. and Curtis GC (1991) Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry 48: 157-162.
2. Abelson JL, Glitz D., Cameron OG, Lee MA, Bronzo M. and Curtis GC (1992) Endocrine, cardiovascular, and behavioral responses to clonidine in patients with panic disorder. Biol Psychiatry 32: 18-25.
3. Albert U., Aguglia E., Maina G. and Bogetto F. (2002) Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 63: 1004-1009.
4. 2 inhalation of subjects with types of specific phobia, panic disorder, or no mental disorder. Am J Psychiatry 154: 1089-1095.
5. Argyropoulos SV, Bailey JE, Hood SD, et al. (2002) Inhalation of 35% CO(2) results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology 27: 715-729.
6. Atmaca M., Tezcan E. and Kuloglu M. (2003) An open clinical trial of reboxetine in the treatment of social phobia. J Clin Psychopharmacol 23: 417-419.
7. 2 challenge ? J Psychopharmacol 17: 252-259.
8. Baldwin DS, Anderson IM, Nutt DJ, et al. (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19: 567-596.
9. Bandelow B., Sengos G., Wedekind D., et al. (1997) Urinary excretion of cortisol, norepinephrine, testosterone, and melatonin in panic disorder. Pharmacopsychiatry 30: 113-117.
10. 2 challenge in panic disorder: optimization by receiver operating characteristic (ROC) analysis. J Psychiatr Res 29: 111-119.
11. Benkelfat C., Mefford IN, Masters CF, et al. (1991) Plasma catecholamines and their metabolites in obsessive-compulsive disorder. Psychiatry Res 37: 321-331.
12. Bertani A., Perna G., Migliarese G., et al. (2004) Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry 37: 206-210.
13. Bose A., Korotzer A., Gommoll C. and Li D. (2008) Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress Anxiety 25: 854-861.
14. Bracha HS, Garcia-Rill E., Mrak RE and Skinner R. (2005) Postmortem locus coeruleus neuron count in three American veterans with probable or possible war-related PTSD. J Neuropsychiatry Clin Neurosci 17: 503-509.
15. Brambilla F., Bellodi L., Arancio C., Nobile P. and Perna G. (1995 a) Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder. Psychoneuroendocrino 20: 11-19.
16. Brambilla F., Bellodi L., Perna G., et al. (1997) Noradrenergic receptor sensitivity in obsessive compulsive disorder: II. Cortisol response to acute clonidine administration. Psychiatry Res 69: 163-168.
17. Brambilla F., Perna G., Garberi A., Nobile P. and Bellodi L. (1995 b) Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. Psychoneuroendocrino 20: 1-9.
18. Bremner JD, Krystal JH, Southwick SM and Charney DS (1996 a) Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse 23: 28-38.
19. Bremner JD, Krystal JH, Southwick SM and Charney DS (1996 b) Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse 23: 39-51.
20. 2 challenge test in patients with social phobia. Psychiatry Res 71 (1). 41-48.
21. Cameron OG (1994) Adrenergic Dysfunction and Psychobiology, 1st edn. Washington DC: American Psychiatric Press.
22. Cameron OG, Abelson JL and Young EA (2004) Anxious and depressive disorders and their comorbidity: effect on central nervous system noradrenergic function. Biol Psychiatry 56: 875-883.
23. Cameron OG, Lee MA, Curtis GC and McCann DS (1987) Endocrine and physiological changes during 'spontaneous' panic attacks. Psychoneuroendocrino 12 (5). 321-331.
24. Cameron OG, Smith CB, Hollingsworth PJ, Nesse RM and Curtis GC (1984) Platelet alpha 2-adrenergic receptor binding and plasma catecholamines. Before and during imipramine treatment in patients with panic anxiety. Arch Gen Psychiatry 41: 1144-1148.
25. Cameron OG, Smith CB, Lee MA, Hollingsworth PJ, Hill EM and Curtis GC (1990) Adrenergic status in anxiety disorders: platelet alpha 2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects. Biol Psychiatry 28: 3-20.
26. Campbell WB, Johnson AR, Callahan KS and Graham RM (1981) Anti-platelet activity of beta-adrenergic antagonists: inhibition of thromboxane synthesis and platelet aggregation in patients receiving long-term propranolol treatment. Lancet 2: 1382-1384.
27. Charney DS and Heninger GR (1986) Alpha 2-adrenergic and opiate receptor blockade. Synergistic effects on anxiety in healthy subjects. Arch Gen Psychiatry 43: 1037-1041.
28. Charney DS, Heninger GR and Breier A. (1984) Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41: 751-763.
29. Charney DS, Innis RB, Duman RS, Woods SW and Heninger GR (1989 a) Platelet alpha-2-receptor binding and adenylate cyclase activity in panic disorder. Psychopharmacology (Berl) 98: 102-107.
30. Charney DS, Woods SW, Goodman WK and Heninger GR (1987) Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 144: 1030-1036.
31. Charney DS, Woods SW and Heninger GR (1989 b) Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. Psychiatry Res 27: 173-182.
32. Charney, DS, Woods, SW, Krystal, JH, Nagy LM and Heninger, GR (1992) Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand 86: 273-82.
33. Clark DM (1988) A cognitive model of panic attacks. In: Rachman S, Maser J (eds). Panic: Psychological Perspectives. Hillsdale, New Jersey: Erlbaum.
34. Coplan JD, Papp LA, Martinez J., et al. (1995) Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. Am J Psychiatry 152: 619-622.
35. Coupland N., Glue P. and Nutt DJ (1992) Challenge tests: assessment of the noradrenergic and GABA systems in depression and anxiety disorders. Mol Aspects Med 13: 221-247.
36. Dannon PN, Iancu I. and Grunhaus L. (2002) The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Hum Psychopharmacol 17: 329-333.
37. Davidson JR, Bose A. and Wang Q. (2005) Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 66: 1441-1446. (Pubitemid 41779543)
38. Den Boer JA and Westenberg HG (1988) Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3: 59-74.
39. Denys D., van Megen HJ, van der Wee N. and Westenberg HG (2004) A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 65: 37-43.
40. Elsworth JD, Redmond DE Jr and Roth RH (1982) Plasma and cerebrospinal fluid 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) as indices of brain norepinephrine metabolism in primates. Brain Res 235: 115-124.
41. Eriksson E., Westberg P., Alling C., Thuresson K. and Modigh K. (1991) Cerebrospinal fluid levels of monoamine metabolites in panic disorder. Psychiatry Res 36: 243-251.
42. Esler M., Eikelis N., Schlaich M., et al. (2008) Human sympathetic nerve biology: parallel influences of stress and epigenetics in essential hypertension and panic disorder. Ann N Y Acad Sci 1148: 338-348.
43. Esler M., Jennings G. and Lambert G. (1989) Measurement of overall and cardiac norepinephrine release into plasma during cognitive challenge. Psychoneuroendocrino 14: 477-481.
44. Gann H., Riemann D., Stoll S., Berger M. and Muller WE (1995) Growth-hormone response to clonidine in panic disorder patients in comparison to patients with major depression and healthy controls. Pharmacopsychiatry 28: 80-83.
45. Garvey MJ, Tollefson GD and Orsulak PJ (1987) Elevations of urinary MHPG in depressed patients with panic attacks. Psychiat Res 20: 183-187.
46. George DT, Adinoff B., Ravitz B., et al. (1990) A cerebrospinal fluid study of the pathophysiology of panic disorder associated with alcoholism. Acta Psychiatr Scand 82: 1-7.
47. Geracioti TD Jr, Baker DG, Ekhator NN, et al. (2001) CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry 158: 1227-1230.
48. Gil-Ad I., Gurewitz R., Marcovici O., Rosenfeld J. and Laron Z. (1984) Effect of aging on human plasma growth hormone response to clonidine. Mech Ageing Dev 27: 97-100.
49. Gorman JM, Kent J., Martinez J., Browne S., Coplan J. and Papp LA (2001) Physiological changes during carbon dioxide inhalation in patients with panic disorder, major depression, and premenstrual dysphoric disorder: evidence for a central fear mechanism. Arch Gen Psychiatry 58: 125-131.
50. Greene KA and Faull KF (1989) Relationship between plasma and cerebrospinal fluid norepinephrine and dopamine metabolites in a nonhuman primate. J Neurochem 53: 1007-1013.
51. Gurguis GN, Andrews R., Antai-Otong D., et al. (1999 a) Platelet alpha2-adrenergic receptor coupling efficiency to Gi protein in subjects with post-traumatic stress disorder and normal controls. Psychopharmacology (Berl) 141: 258-266. (Pubitemid 29196075)
52. Gurguis GN, Blakeley JE, Antai-Otong D., et al. (1999 b) Adrenergic receptor function in panic disorder. II. Neutrophil beta 2 receptors: Gs protein coupling, effects of imipramine treatment and relationship to treatment outcome. J Psychiatr Res 33: 309-322. (Pubitemid 29267634)
53. Gurguis GN, Vo SP, Blakeley J., Orsulak PJ and Rush AJ (1999 c) Characteristics of norepinephrine and clonidine displacement of [3H]yohimbine binding to platelet alpha2-adrenoreceptors in healthy volunteers. Psychiatry Res 85: 305-314.
54. Guyenet PG (1997) Is the hypotensive effect of clonidine and related drugs due to imidazoline binding sites ? Am J Physiol 273: R1580-1584.
55. Haddjeri N., Blier P. and de Montigny C. (1996) Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther 277: 861-871.
56. Head GA, Chan CK and Burke SL (1998) Relationship between imidazoline and alpha2-adrenoceptors involved in the sympatho-inhibitory actions of centrally acting antihypertensive agents. J Auton Nerv Syst 72: 163-169.
57. Hasenne, M., Pitchot, W. and Ansseau, M. (1991) The clonidine test in posttraumatic stress disorder. Am J Psychiatry 148: 810-811.
58. Hirshoren N., Tzoran I., Makrienko I., et al. (2002) Menstrual cycle effects on the neurohumoral and autonomic nervous systems regulating the cardiovascular system. J Clin Endocrinol Metab 87: 1569-1575.
59. Hoehn-Saric R., Ninan P., Black DW, et al. (2000) Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry 57: 76-82.
60. Hoeldtke RD and Cilmi KM (1985) Effects of aging on catecholamine metabolism. J Clin Endocrinol Metab 60: 479-484.
61. Hohoff C., Domschke K., Schwarte K., et al. (2008) Sympathetic activity relates to adenosine A(2A) receptor gene variation in blood-injury phobia. J Neural Transm 116: 659-662.
62. Hollander E., DeCaria C., Nitescu A., et al. (1991) Noradrenergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to clonidine and comparison to healthy controls. Psychiatry Res 37: 161-177.
63. Hood SD, Melichar JK, Taylor LG, Kalk N., Edwards TR, Hince DA, et al. (2010) Noradrenergic function in generalized anxiety disoder: impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge. J Psychopharmacol 00: 1-9 (accessed 12 May 2010 ).
64. Hunt GE, O'Sullivan BT, Johnson GF and Smythe GA (1986) Growth hormone and cortisol secretion after oral clonidine in healthy adults. Psychoneuroendocrino 11: 317-325.
65. Kabayama Y., Kato Y., Murakami Y., Tanaka H. and Imura H. (1986) Stimulation by alpha-adrenergic mechanisms of the secretion of growth hormone-releasing factor (GRF) from perifused rat hypothalamus. Endocrinology 119: 432-434.
66. Kaufman J. and Charney D. (2000) Comorbidity of mood and anxiety disorders. Depress Anxiety 12 (Suppl 1). 69-76.
67. Kaye J., Buchanan F., Kendrick A., et al. (2004) Acute carbon dioxide exposure in healthy adults: evaluation of a novel means of investigating the stress response. J Neuroendocrinol 16: 256-264.
68. Kehne JH and Davis M. (1985) Central noradrenergic involvement in yohimbine excitation of acoustic startle: effects of DSP4 and 6-OHDA. Brain Res 330: 31-41.
69. Klein DF (1993) False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch Gen Psychiatry 50: 306-317.
70. Klein DF and Fink M. (1962) Psychiatric reaction patterns to imipramine. Am J Psychiatry 119: 432-438.
71. Lambert GW, Kaye DM, Vaz M., et al. (1995) Regional origins of 3-methoxy-4-hydroxyphenylglycol in plasma: effects of chronic sympathetic nervous activation and denervation, and acute reflex sympathetic stimulation. J Auton Nerv Syst 55: 169-178.
72. Lambert GW, Thompson JM, Turner AG, et al. (1997) Cerebral noradrenaline spillover and its relation to muscle sympathetic nervous activity in healthy human subjects. J Auton Nerv Syst 64: 57-64.
73. Lanes R., Herrera A., Palacios A. and Moncada G. (1983) Decreased secretion of cortisol and ACTH after oral clonidine administration in normal adults. Metabolism 32: 568-570.
74. Leckman JF, Goodman WK, Anderson GM, et al. (1995) Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacol 12: 73-86.
75. Lee MA, Cameron OG, Gurguis GN, et al. (1990) Alpha 2-adrenoreceptor status in obsessive-compulsive disorder. Biol Psychiatry 27: 1083-1093.
76. Marazziti D., Baroni S., Masala I., et al. (2004) Platelet alpha2-adrenoreceptors in obsessive-compulsive disorder. Neuropsychobiology 49: 81-83.
77. Marshall RD, Blanco C., Printz D., Liebowitz MR, Klein DF and Coplan J. (2002) A pilot study of noradrenergic and HPA axis functioning in PTSD vs. panic disorder. Psychiatry Res 110: 219-230.
78. Matussek N., Ackenheil M. and Herz M. (1984) The dependence of the clonidine growth hormone test on alcohol drinking habits and the menstrual cycle. Psychoneuroendocrino 9: 173-177.
79. Morgan CA 3rd, Grillon C., Southwick SM, et al. (1995) Yohimbine facilitated acoustic startle in combat veterans with post-traumatic stress disorder. Psychopharmacology (Berl) 117: 466-471.
80. Murburg MM, McFall ME, Lewis N. and Veith RC (1995) Plasma norepinephrine kinetics in patients with posttraumatic stress disorder. Biol Psychiatry 38: 819-825.
81. Murphy SE, Yiend J., Lester KJ, Cowen PJ and Harmer CJ (2008) Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers. Int J Neuropsychopharmacol 12: 169-179.
82. Nutt DJ (2005) Anxiety Disorders. Oxford: Blackwell Publishing. Nutt DJ (1989) Altered central alpha 2-adrenoceptor sensitivity in panic disorder. Arch Gen Psychiatry 46: 165-169.
83. Nutt DJ (1996) The psychopharmacology of anxiety. Br J Hosp Med 55: 187-191.
84. Nutt DJ and Fraser S. (1987) Platelet binding studies in panic disorder. J Affect Disord 12: 7-11.
85. Nutt DJ and Molyneux SG (1986) The effect of clonidine on plasma MHPG: evidence against tonic alpha 2-adrenoceptor control of noradrenergic function. Psychopharmacology (Berl) 90: 509-512.
86. 2 challenge in panic and mood disorders. J Affective Disorders 33 (3). 189-194.
87. 2 challenges. Am J Psychiatry 152 (1). 85-89.
88. 2 after one week of treatment with paroxetine and reboxetine: a double-blind, randomized study. J Clin Psychopharmacol 24: 277-282.
89. Perna G., Bussi R., Allevi L. and Bellodi L. (1999) Sensitivity to 35% carbon dioxide in patients with generalized anxiety disorder. J Clin Psychiatry 60 (6). 379-384.
90. Piletz JE, Halaris A., Nelson J., Qu Y. and Bari M. (1996) Platelet I1-imidazoline binding sites are elevated in depression but not generalized anxiety disorder. J Psychiatr Res 30: 147-168.
91. Poehlman ET, Gardner AW and Goran MI (1992) Influence of endurance training on energy intake, norepinephrine kinetics, and metabolic rate in older individuals. Metabolism 41: 941-948.
92. Pollack M., Mangano R., Entsuah R., Tzanis E., Simon NM and Zhang Y. (2007) A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl) 194: 233-242.
93. Rasmussen SA, Goodman WK, Woods SW, Heninger GR and Charney DS (1987) Effects of yohimbine in obsessive compulsive disorder. Psychopharmacology (Berl) 93: 308-313.
94. Reid JL, Wing LM, Mathias CJ, Frankel HL and Neill E. (1977) The central hypotensive effect of clonidine. Studies in tetraplegic subjects. Clin Pharmacol Ther 21: 375-381.
95. Ribeiro L., Busnello JV, Kauer-Sant'Anna M., et al. (2001) Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 34: 1303-1307.
96. Richerson GB (2004) Serotonergic neurons as carbon dioxide sensors that maintain pH homeostasis. Nat Rev Neurosci 5: 449-461.
97. Sand PG, Mori T., Godau C., et al. (2002) Norepinephrine transporter gene (NET) variants in patients with panic disorder. Neurosci Lett 333: 41-44.
98. Schittecatte M., Ansseau M., Charles G., et al. (1992) Growth hormone response to clonidine in male patients with panic disorder untreated by antidepressants. Psychol Med 22: 1059-1062.
99. Schittecatte M., Charles G., Machowski R. and Wilmotte J. (1989) Growth hormone response to clonidine in untreated depressed patients. Psychiatry Res 29: 199-206. (Pubitemid 19222816)
100. Seedat S., van Rheede van Oudtshoorn E., Muller JE, Mohr N. and Stein DJ (2003) Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol 18: 279-284.
101. Sheehan DV, Coleman JH, Greenblatt DJ, et al. (1984) Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. J Clin Psychopharmacol 4: 66-75.
102. Sher L., Oquendo MA, Li S., et al. (2005) Higher cerebrospinal fluid homovanillic acid levels in depressed patients with comorbid posttraumatic stress disorder. Eur Neuropsychopharmacol 15: 203-209.
103. Siever LJ, Insel TR, Jimerson DC, et al. (1983) Growth hormone response to clonidine in obsessive-compulsive patients. Br J Psychiatry 142: 184-187.
104. Smajkic A., Weine S., Djuric-Bijedic Z., Boskailo E., Lewis J. and Pavkovic I. (2001) Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. J Trauma Stress 14: 445-452.
105. Southwick SM, Krystal JH, Bremner JD, et al. (1997) Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry 54: 749-758.
106. Southwick SM, Krystal JH, Morgan CA, et al. (1993) Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry 50: 266-274.
107. Southwick SM, Morgan CA 3rd, Charney DS and High JR (1999) Yohimbine use in a natural setting: effects on posttraumatic stress disorder. Biol Psychiatry 46: 442-444.
108. Spivak B., Strous RD, Shaked G., Shabash E., Kotler M. and Weizman A. (2006) Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. J Clin Psychopharmacol 26: 152-156.
109. Stahl SM, Mendels J. and Schwartz GE (2002) Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials. J Clin Psychopharmacol 22: 388-392.
110. Stein DJ (2006) Advances in understanding the anxiety disorders: the cognitive-affective neuroscience of 'false alarms'. Ann Clin Psychiatry 18: 173-182.
111. Stein MB, Tancer ME and Uhde TW (1992) Heart rate and plasma norepinephrine responsivity to orthostatic challenge in anxiety disorders. Comparison of patients with panic disorder and social phobia and normal control subjects. Arch Gen Psychiatry 49: 311-317.
112. Takano A., Varrone A., Gulyas B., Karlsson P., Tauscher J. and Halldin C. (2008) Mapping of the norepinephrine transporter in the human brain using PET with (S,S)-[18F]FMeNER-D2. Neuroimage 42: 474-482.
113. Talesnik B., Berzak E., Ben-Zion I., Kaplan Z. and Benjamin J. (2007) Sensitivity to carbon dioxide in drug-naive subjects with post-traumatic stress disorder. J Psychiatr Res 41: 451-454.
114. Tam SW, Worcel M. and Wyllie M. (2001) Yohimbine: a clinical review. Pharmacol Ther 91: 215-243.
115. Tancer ME, Mailman RB, Stein MB, Mason GA, Carson SW and Golden RN (1994) Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia. Anxiety 1: 216-223.
116. Tancer ME, Stein MB and Uhde TW (1993) Growth hormone response to intravenous clonidine in social phobia: comparison to patients with panic disorder and healthy volunteers. Biol Psychiatry 34: 591-595.
117. Tsuji M., Yamane H., Yamada N., Iida H., Taga C. and Myojin T. (1986) Studies on 3-methoxy-4-hydroxyphenylglycol (MHPG) and 3,4-dihydroxyphenylglycol (DHPG) levels in human urine, plasma and cerebrospinal fluids, and their significance in studies of depression. Jpn J Psychiatry Neurol 40: 47-56.
118. Turton MB and Deegan T. (1974) Circadian variations of plasma catecholamine, cortisol and immunoreactive insulin concentrations in supine subjects. Clin Chim Acta 55: 389-397.
119. Tyacke RJ, Robinson ES, Lalies MD, Hume SP, Hudson AL and Nutt DJ (2005) Estimation of endogenous noradrenaline release in rat brain in vivo using [3H]RX 821002. Synapse 55: 126-132.
120. Uhde TW, Stein MB, Vittone BJ, et al. (1989) Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder. Arch Gen Psychiatry 46: 170-177.
121. Uhde TW, Vittone BJ, Siever LJ, Kaye WH and Post RM (1986) Blunted growth hormone response to clonidine in panic disorder patients. Biol Psychiatry 21: 1081-1085.
122. Valcavi R., Dieguez C., Page MD, et al. (1988) Alpha-2-adrenergic pathways release growth hormone via a non-GRF-dependent mechanism in normal human subjects. Clin Endocrinol (Oxf) 29: 309-316.
123. Verburg C., Griez E. and Meijer J. (1994) A 35% carbon dioxide challenge in simple phobias. Acta Psychiatr Scand 90 (6). 420-423.
124. Versiani M., Cassano G., Perugi G., et al. (2002) Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 63: 31-37.
125. Wilkinson DJ, Thompson JM, Lambert GW, et al. (1998) Sympathetic activity in patients with panic disorder at rest, under laboratory mental stress, and during panic attacks. Arch Gen Psychiatry 55: 511-520.
126. Wolpe J. (1973) The Practice of Behaviour Therapy. New York: Pergamon.
127. Wong EH, Sonders MS, Amara SG, et al. (2000) Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47: 818-829.
128. Yehuda R., Siever LJ, Teicher MH, et al. (1998) Plasma norepinephrine and 3-methoxy-4-hydroxyphenylglycol concentrations and severity of depression in combat posttraumatic stress disorder and major depressive disorder. Biol Psychiatry 44: 56-63.
129. Yoshioka M., Matsumoto M., Togashi H., Smith CB and Saito H. (1992) Alpha 2-adrenoceptor modulation of 5-HT biosynthesis in the rat brain. Neurosci Lett 139: 53-56.